The Effect of Vidian Neurectomy on the Ocular Surface - The Primary Results from a Six-Month Pilot Study.

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics Therapeutics and Clinical Risk Management Pub Date : 2024-06-07 eCollection Date: 2024-01-01 DOI:10.2147/TCRM.S455608

Xichen Wan, Tong Lin, Yunzhen Luo, Jiaxu Hong, Jingyi Cheng, Keqing Zhao

{"title":"The Effect of Vidian Neurectomy on the Ocular Surface - The Primary Results from a Six-Month Pilot Study.","authors":"Xichen Wan, Tong Lin, Yunzhen Luo, Jiaxu Hong, Jingyi Cheng, Keqing Zhao","doi":"10.2147/TCRM.S455608","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the effect of vidian neurectomy (VN) on the ocular surface and the possibility of dry eye in the treatment of allergic rhinitis.Methods: Twelve participants were recruited in this prospective study. Prior to and after 1 and 6 months of VN, an ocular surface disease index (OSDI) questionnaire was obtained, and the Schirmer's tear test (STT), break-up time (BUT), corneal fluorescence staining (CFS) score, and Keratograph 5M were used to evaluate the ocular surface condition.Results: Two patients (16.67%) met the dry eye diagnosis criteria one month after surgery; however, their symptoms were relieved after to 3-4 months and none of them met the diagnostic criteria for dry eye after six months. Compared with the baseline values, the STT was significantly reduced (P=0.002), while the tear meniscus height (TMH) (P=0.262), break-up time (BUT) (P=0.916), first keratographic tear film break-up time (NK-BUTfirst) (P=0.791), and average keratographic break-up time (NK-BUTave) (P=0.970) did not change significantly 6 months after surgery. The degree of STT decreased from baseline to 6-month and was related to the basic STT (ρ= 0.837, P=0.001) and sex (ρ= -0.584, P= 0.026) but not to age, OSDI score, BUT, NK-BUTfirst, NK-BUTave or CFS (all P>0.05). Among these factors, STT at baseline was confirmed to be a predictor of a decline in tear secretion after surgery (B = 0.731, P<0.001).Conclusion: In this 6-month prospective pilot study, decreased tearing was observed after VN, but this decrease did not increase the possibility of dry eyes.","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11166153/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S455608","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the effect of vidian neurectomy (VN) on the ocular surface and the possibility of dry eye in the treatment of allergic rhinitis.

Methods: Twelve participants were recruited in this prospective study. Prior to and after 1 and 6 months of VN, an ocular surface disease index (OSDI) questionnaire was obtained, and the Schirmer's tear test (STT), break-up time (BUT), corneal fluorescence staining (CFS) score, and Keratograph 5M were used to evaluate the ocular surface condition.

Results: Two patients (16.67%) met the dry eye diagnosis criteria one month after surgery; however, their symptoms were relieved after to 3-4 months and none of them met the diagnostic criteria for dry eye after six months. Compared with the baseline values, the STT was significantly reduced (P=0.002), while the tear meniscus height (TMH) (P=0.262), break-up time (BUT) (P=0.916), first keratographic tear film break-up time (NK-BUT_first) (P=0.791), and average keratographic break-up time (NK-BUT_ave) (P=0.970) did not change significantly 6 months after surgery. The degree of STT decreased from baseline to 6-month and was related to the basic STT (ρ= 0.837, P=0.001) and sex (ρ= -0.584, P= 0.026) but not to age, OSDI score, BUT, NK-BUT_first, NK-BUT_ave or CFS (all P>0.05). Among these factors, STT at baseline was confirmed to be a predictor of a decline in tear secretion after surgery (B = 0.731, P<0.001).

Conclusion: In this 6-month prospective pilot study, decreased tearing was observed after VN, but this decrease did not increase the possibility of dry eyes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Vidian 神经切除术对眼表的影响 - 六个月试点研究的初步结果。

目的：评估吠陀神经切除术（VN）对眼表的影响以及在治疗过敏性鼻炎过程中出现干眼症的可能性：这项前瞻性研究招募了 12 名参与者。方法：这项前瞻性研究共招募了 12 名参与者，在接受神经阻断术（VN）1 个月和 6 个月之前和之后，进行了眼表疾病指数（OSDI）问卷调查，并使用施尔默泪液试验（STT）、泪液破裂时间（BUT）、角膜荧光染色（CFS）评分和 5M 角膜塑形镜（Keratograph 5M）评估眼表状况：两名患者（16.67%）在术后一个月达到了干眼症诊断标准，但他们的症状在 3-4 个月后有所缓解，没有人在六个月后达到干眼症诊断标准。与基线值相比，术后 6 个月 STT 明显降低（P=0.002），而泪液半月板高度（TMH）（P=0.262）、泪液破裂时间（BUT）（P=0.916）、首次角膜泪液膜破裂时间（NK-BUTfirst）（P=0.791）和平均角膜泪液膜破裂时间（NK-BUTave）（P=0.970）均无明显变化。STT 的程度从基线到 6 个月有所下降，与基本 STT（ρ= 0.837，P=0.001）和性别（ρ= -0.584，P= 0.026）有关，但与年龄、OSDI 评分、BUT、NK-BUTfirst、NK-BUTave 或 CFS 无关（均 P>0.05）。在这些因素中，基线 STT 被证实是术后泪液分泌下降的预测因素（B = 0.731，PC 结论：在这项为期 6 个月的前瞻性试验研究中，观察到 VN 术后泪液减少，但这种减少并不会增加眼睛干涩的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.